Arcturus Therapeutics Holdings Inc. (ARCT) stock
ARCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/303% below fair value
$8.36−0.08 (-0.95%)
Close on Nov 13, 2026Market cap $237.62MP/E –Yield –
Arcturus Therapeutics EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Arcturus Therapeutics's EV/EBITDA was 9.2× on Jan 31, 2024.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2024 | Jan 31, 2024 | 9.2× | +0.6 |
| 2023 | Dec 29, 2023 | 8.6× | – |
See a number that looks wrong?